: Specialty medicines (HIV, Oncology, Respiratory) now drive over 40% of revenue.
: Strong market position with Shingrix (shingles) and Arexvy (RSV). buy gsk shares
: 3.2% to 3.5% (annualized ~70p expected for 2026). Market Cap : ~£110 Billion. 📈 Investment Thesis: Why Buy? : Specialty medicines (HIV, Oncology, Respiratory) now drive
: Trades at ~10.3x to 14.5x 2026 adjusted earnings. : Specialty medicines (HIV
: Settled ~93% (80,000 cases) of U.S. Zantac litigation for $2.2 billion, removing a major long-term overhang. ⚠️ Risks to Consider Stock Story: GSK - The Merchants Trust
: Five major product approvals were achieved in 2025; two more expected in 2026 for bepirovirsen and tebipenem .
: Specialty medicines (HIV, Oncology, Respiratory) now drive over 40% of revenue.
: Strong market position with Shingrix (shingles) and Arexvy (RSV).
: 3.2% to 3.5% (annualized ~70p expected for 2026). Market Cap : ~£110 Billion. 📈 Investment Thesis: Why Buy?
: Trades at ~10.3x to 14.5x 2026 adjusted earnings.
: Settled ~93% (80,000 cases) of U.S. Zantac litigation for $2.2 billion, removing a major long-term overhang. ⚠️ Risks to Consider Stock Story: GSK - The Merchants Trust
: Five major product approvals were achieved in 2025; two more expected in 2026 for bepirovirsen and tebipenem .